Updated: 28th June 2026
Reviewed by: David Small BSc (Hons), MSc, MTOPRA (Founder and CEO)
Understanding the Two Regulatory Frameworks
In this blog, we’ll explain who the MDCG is, what their role involves, and why their guidance documents are essential for anyone working within the European medical device sector. We’ll also highlight some of the most important MDCG guidance documents that you should be aware of.
Need an Introduction to UK Medical Device Regulations?
This article compares EU MDR and UK MDR requirements for manufacturers navigating both markets. If you're looking for a complete overview of UK medical device regulations, including UKCA marking, MHRA registration, UK Responsible Person requirements, classification and post-market surveillance, read our Complete Guide to UK Medical Device Regulations.
What is the EU MDR?
The EU Medical Device Regulation (Regulation (EU) 2017/745) is the legislation that governs medical devices sold in the European Union. It replaced the former Medical Devices Directive (93/42/EEC) in May 2021. The EU MDR introduced more stringent requirements for clinical evidence, post-market surveillance, and device classification.
What is the UK MDR?
The UK Medical Devices Regulations 2002 (as amended), incorporates the former EU MDD and now applies to the Great Britain (England, Scotland, and Wales) market. It has been retained in UK law post-Brexit, but the MHRA (Medicines and Healthcare products Regulatory Agency) has announced plans to revise and modernise it.
Currently:
CE marking is accepted in Great Britain until 30 June 2030 for many devices (depending on type and registration). This is likely to be extended indefinitely from 2026/2027 based on the MHRA’s review of how medical devices are regulated in the UK.
For Northern Ireland, EU MDR applies due to the Northern Ireland Protocol.
Key Differences Between EU MDR and UK MDR
| Area | EU MDR | UK MDR |
|---|---|---|
| Market Scope | EU (including Northern Ireland) | Great Britain |
| Marking | CE Mark | CE Mark (until 2030 or beyond) or UKCA |
| Economic Operators | Requires EU Authorised Representative | Requires UK Responsible Person |
| Regulatory Authority | European Commission & Competent Authorities | MHRA |
| Notified Bodies | EU Notified Bodies | UK Approved Bodies |
| Clinical Evaluation | Mandatory for all risk classes with stricter scrutiny | Based on legacy EU MDD, but evolving |
| Post-Market Surveillance | Increased emphasis with formal PMS and PSURs | Less prescriptive, but reforms planned |
Step-by-Step Guide to Compliance
1. Determine Market Access Goals
Decide where your medical device will be sold: the EU, the UK, or both. This determines whether you need CE marking, UKCA marking, or both, and which regulations and economic operators apply.
2. Conduct Proper Device Classification
Under both frameworks, classification determines the level of conformity assessment. The EU MDR has reclassified many devices to higher risk classes. Be sure to review classification rules under Annex VIII (EU MDR) and compare them with the UK MDR’s MDD-based rules.
3. Appoint the Required Economic Operator(s)
For EU access: EU Authorised Representative
For GB access: UK Responsible Person
These entities must be clearly identified on device labelling and technical documentation.
4. Select an Appropriate Notified or Approved Body
Your Notified Body must be designated under the EU MDR for CE marking, or an Approved Body designated by MHRA for UKCA marking. Ensure the scope of designation covers your product type.
5. Prepare Technical Documentation
This includes:
General Safety and Performance Requirements (GSPRs) in the EU
Essential Requirements (ERs) in the UK
Detailed design files, risk management (ISO 14971), clinical evaluation reports, PMS plans, and labelling.
Tip: Align your documentation to the EU MDR standards as a baseline—it often satisfies or exceeds UK requirements.
6. Implement a Quality Management System (QMS)
For most devices, an ISO 13485-certified QMS is expected under both regimes. You must document processes for:
Production and traceability
7. Register with the Relevant Authorities
EU: National Competent Authorities via EUDAMED (voluntary until fully functional)
UK: Register your device and economic operator with MHRA within the relevant timelines based on device class.
Dual Compliance Tips for Manufacturers
Use Harmonised Systems: Design your QMS, technical documentation, and labelling to meet EU MDR standards. This generally ensures UK MDR compliance as well.
Stay Up to Date: The UK is revising its medical device regulations. Keep a close eye on MHRA guidance and consultations.
Label Smartly: If you’re marketing in both regions, consider combined CE/UKCA marking strategies where possible.
Coordinate Economic Operators: Choose EU and UK reps who can work in harmony, especially for global surveillance and communication workflows.
The Future: What’s Changing?
The MHRA plans to roll out a new regulatory framework for Great Britain, originally targeted for 2025 but now phased. Anticipated updates include:
Greater alignment with EU MDR principles
Enhanced device registration and surveillance
Greater use of digital technologies (e.g., Unique Device Identifiers)
Manufacturers must monitor transitional periods for CE acceptance and prepare early for full UKCA compliance.
How Patient Guard Can Help
Navigating dual compliance with the EU MDR and UK MDR requires planning, diligence, and strategic coordination. Manufacturers should treat this not as a box-ticking exercise but as a holistic quality and safety initiative.
At Patient Guard, we help clients across the UK and EU with:
Device classification
QMS and technical documentation support
Authorised Representative and Responsible Person services
Regulatory strategy and market access
Frequently Asked Questions Relating to EU MDR and UK MDR
Yes, but only temporarily. CE marking is accepted for placing devices on the Great Britain market until 30 June 2030 for most devices (subject to specific timelines and conditions set by MHRA). After that, devices must carry the UKCA mark unless new regulations extend the transition. However, Northern Ireland continues to require CE marking due to the NI Protocol.
Not necessarily. If your documentation meets the EU MDR’s more stringent requirements, it typically satisfies the UK MDR as well. However, you will need to include UK-specific elements—such as appointing a UK Responsible Person, UK declarations of conformity, and possibly UK-specific labelling or vigilance procedures.
Both roles serve as legal representatives for non-EU or non-UK manufacturers, but they are specific to each market:
An EU Authorised Representative (EU AR) is required to place products on the EU market and ensures compliance with EU MDR.
A UK Responsible Person (UK RP) is required for access to Great Britain and fulfills similar duties under UK MDR, including device registration with MHRA and cooperation with UK authorities.
You will need both if you sell in both regions and are based outside the EU and UK.
Patient Guards Recent Posts
Cosmetic Product Safety Report (CPSR): A Complete Guide to UK Cosmetic Compliance
Before a cosmetic product can legally be placed on the UK market, manufacturers and Responsible Persons must demonstrate that it is safe for human use under normal or reasonably foreseeable conditions. The Cosmetic Product Safety Report (CPSR) is one of the most important regulatory documents required under the UK Cosmetics Regulation. This guide explains what a CPSR is, who can prepare one, what information it must contain, how it relates to the Product Information File (PIF) and how it supports legal cosmetic compliance.
IVDR PMPF Explained: A Complete Guide to Post-Market Performance Follow-up
Post-Market Performance Follow-up (PMPF) is a fundamental requirement under the EU In Vitro Diagnostic Regulation (IVDR), ensuring that manufacturers continually monitor the scientific validity, analytical performance and clinical performance of their in vitro diagnostic medical devices after CE marking. This guide explains IVDR PMPF requirements, PMPF Plans, PMPF Reports, Annex XIII expectations and how ongoing performance monitoring supports continued regulatory compliance throughout the device lifecycle.
IVDR Scientific Validity Explained: A Complete Guide for Manufacturers
Scientific Validity is the first pillar of IVDR Performance Evaluation and provides the scientific foundation demonstrating that an analyte or biomarker is associated with a specific clinical condition or physiological state. This guide explains Scientific Validity under Regulation (EU) 2017/746, including literature reviews, Scientific Validity Reports, Annex XIII requirements, evidence appraisal and how Scientific Validity supports successful CE marking.
Patient Guards Related Services
Patient Guards Regulatory Tools
Need Training?
Do you need training on Quality Management Systems or EU MDR/ EU IVDR? then check out our training courses.
